TY - JOUR
T1 - Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma? A comparison with AMACR
AU - Wu, Xiaojun
AU - Zayzafoon, Majd
AU - Zhang, Xinzhi
AU - Hameed, Omar
PY - 2011/8
Y1 - 2011/8
N2 - Our aim was to compare the usefulness of fatty acid synthase (FASn) with that of α-methylacyl coenzyme-A racemase (AMACR) in the diagnosis of prostatic adenocarcinoma. The expression of these 2 markers was compared in a tissue microarray containing 62 foci of benign glands and 36 foci of prostatic adenocarcinoma. Similar to AMACR, there was significantly higher FASn expression in adenocarcinoma compared with that in benign glands. The optimal accuracy rate and area under curve (AUC) by receiver operating characteristic analysis for FASn were not significantly different from those for AMACR (accuracy, 80% vs 87%; AUC, 0.942 vs 0.956; P for both, > .05). Moreover, in cases with coexistent malignant and benign glands on the same core, FASn could selectively distinguish a proportion of cases (17/21 [81%]) similar to using AMACR. We conclude that FASn may aid in the diagnosis of prostatic adenocarcinoma, at least to supplement AMACR as another positive marker of carcinoma and potentially increase diagnostic accuracy.
AB - Our aim was to compare the usefulness of fatty acid synthase (FASn) with that of α-methylacyl coenzyme-A racemase (AMACR) in the diagnosis of prostatic adenocarcinoma. The expression of these 2 markers was compared in a tissue microarray containing 62 foci of benign glands and 36 foci of prostatic adenocarcinoma. Similar to AMACR, there was significantly higher FASn expression in adenocarcinoma compared with that in benign glands. The optimal accuracy rate and area under curve (AUC) by receiver operating characteristic analysis for FASn were not significantly different from those for AMACR (accuracy, 80% vs 87%; AUC, 0.942 vs 0.956; P for both, > .05). Moreover, in cases with coexistent malignant and benign glands on the same core, FASn could selectively distinguish a proportion of cases (17/21 [81%]) similar to using AMACR. We conclude that FASn may aid in the diagnosis of prostatic adenocarcinoma, at least to supplement AMACR as another positive marker of carcinoma and potentially increase diagnostic accuracy.
UR - http://www.scopus.com/inward/record.url?scp=79961001505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79961001505&partnerID=8YFLogxK
U2 - 10.1309/AJCP0Y5QWWYDKCJE
DO - 10.1309/AJCP0Y5QWWYDKCJE
M3 - Article
C2 - 21757596
AN - SCOPUS:79961001505
SN - 0002-9173
VL - 136
SP - 239
EP - 246
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 2
ER -